Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Automated Versus Manual Oxygen Titration With the EMILY.AI Device in Hospitalized Patients With Acute Respiratory Failure

9. november 2026 opdateret af: Aether Tech S.L.

Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Randomized Substudy in a Conventional Hospital Ward

This randomized study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient, second by second, according to oxygen saturation (SpO2), heart rate and respiratory rate measured by a pulse oximeter.

Adults admitted to the pulmonology ward of Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain) with acute respiratory failure are randomly assigned to receive oxygen titrated automatically by EMILY.AI or oxygen managed as usual by the nursing team, from randomization until hospital discharge. All participants wear the device; in the usual-care group it only records data.

The study compares the time patients stay within their target saturation range, episodes of low and high oxygen, nursing workload, oxygen use, length of stay and patient experience. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Background On conventional hospital wards, oxygen is usually given at a fixed flow and saturation is checked about once per nursing shift, so periods of hypoxaemia or hyperoxaemia can go undetected. EMILY.AI combines a medical-grade oxygen valve with an edge-computing fuzzy-logic algorithm that sets the oxygen flow every second, with continuous logging of physiological signals and delivered flow.

Design Prospective, single-blind (participant), randomized, parallel-group study. Participants are randomized 1:1 to the EMILY arm (automatic titration) or the MANUAL arm (usual care with nursing monitoring every 8 hours and a fixed oxygen prescription), using permuted blocks of 4 stratified by main admission diagnosis (COPD exacerbation, pneumonia, interstitial lung disease, other) and prior long-term home oxygen therapy (yes or no). Allocation takes place after eligibility is confirmed and informed consent is signed.

Intervention and follow-up All participants are connected to the EMILY.AI device continuously from randomization until hospital discharge. In the EMILY arm the device titrates oxygen autonomously to keep SpO2 within the target range for the type of respiratory failure (hypoxaemic 91-97%; hypercapnic 91-94%). In the MANUAL arm the device works in fixed mode, recording SpO2, heart rate and respiratory rate without changing the flow, and nurses adjust oxygen as usual. Conventional back-up oxygen is available at all times.

Sample size 100 participants: 80 planned for the main comparison and approximately 20 added by protocol amendment (CIP v8.0) to further validate an adjustment of the algorithm parameter that sets the minimum oxygen flow in hypoxaemic patients. All 100 are randomized in the same way. As a pilot functional validation, no formal sample size calculation was performed.

The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and an exercise substudy (six-minute walk test), registered separately.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Alba Naya Prieto, MD
  • Telefonnummer: +34 915 50 48 00
  • E-mail: alba.naya@fjd.es

Undersøgelse Kontakt Backup

  • Navn: Sarah Beatrice Heili Frades, MD, PhD
  • Telefonnummer: +34 915 50 48 00
  • E-mail: SHeili@fjd.es

Studiesteder

  • Spanien
      • Madrid, Spanien, 28040
        • Hospital Universitario Fundación Jiménez Díaz
        • Kontakt:
          • Sarah Beatrice Heili Frades Zimmermann MD, PhD
          • Telefonnummer: +34 915 50 48 00
          • E-mail: SHeili@fjd.es
        • Kontakt:
        • Ledende efterforsker:
          • Sarah Beatrice Heili Frades Zimmermann, MD, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Men and women aged 18 years or older.
  • Admitted to the general pulmonology ward (Unit 67) of Hospital Universitario Fundación Jiménez Díaz.
  • Acute respiratory failure, defined as baseline arterial PaO2 below 60 mmHg or the need for supplemental oxygen to maintain SpO2 above 90%. Patients on long-term oxygen therapy are eligible if a clinical deterioration requires a higher-than-usual oxygen flow to maintain SpO2 above 90%.
  • Signed informed consent.

Exclusion Criteria:

  • Anatomical abnormalities preventing correct placement of the pulse oximeter.
  • Pregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).
  • Need for non-invasive ventilation or high-flow nasal cannula at admission.
  • Palliative care or limitation of therapeutic effort at admission.
  • Expected hospital stay under 48 hours.
  • Clinical situations expected to determine length of stay independently of oxygen therapy, such as intravenous antibiotics for more than 10 days, scheduled interventional or surgical procedures, active social care needs that may delay discharge, a non-respiratory main admission diagnosis, or acute or decompensated non-respiratory comorbidities.
  • Known or suspected carbon monoxide poisoning or methemoglobinemia.
  • Severe hypercapnia with decompensated respiratory acidosis (pH below 7.30), hemodynamic instability requiring vasoactive drugs, or severe sepsis at admission.
  • Cognitive impairment, behavioral disorder or any circumstance preventing proper use of the device or compliance with study procedures.
  • Simultaneous participation in another interventional clinical trial, or readmission of a patient previously included in this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: EMILY

Automatic oxygen titration by EMILY.AI 24 hours a day from randomization to hospital discharge, targeting SpO2 91-97% (hypoxaemic) or 91-94% (hypercapnic).
Enhed: EMILY.AI closed-loop oxygen titration

Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate to keep SpO2 within a target range. Other names: EMILY.AI Smart Valve
Aktiv komparator: MANUAL

Usual care: fixed oxygen prescription adjusted by nursing staff, with vital signs checked every 8 hours. The EMILY.AI device is connected in fixed mode and only records data.
Andet: Manual oxygen titration

Usual care: oxygen flow set and adjusted by the ward nursing team according to standard practice. The EMILY.AI device stays connected in fixed mode, recording signals but not controlling delivery.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage of time with SpO2 within the target range
Tidsramme: From randomization to hospital discharge, up to 30 days.

Percentage of monitored time with SpO2, measured continuously by the device's pulse oximeter, within the target range for the type of respiratory failure (hypoxaemic 91-97%; hypercapnic 91-94%). Compared between the EMILY and MANUAL arms.
From randomization to hospital discharge, up to 30 days.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of participants with SpO2 in range more than 95% of the time
Tidsramme: From randomization to hospital discharge, up to 30 days.

Proportion of participants in each arm whose SpO2 stays within their target range for more than 95% of the monitored time.
From randomization to hospital discharge, up to 30 days.
Time with SpO2 below the target range
Tidsramme: From randomization to hospital discharge, up to 30 days.

Percentage of monitored time with SpO2 below the target range for the type of respiratory failure (hypoxaemia).
From randomization to hospital discharge, up to 30 days.
Time with SpO2 above the target range
Tidsramme: From randomization to hospital discharge, up to 30 days.

Percentage of monitored time with SpO2 above the target range while oxygen is being delivered (hyperoxaemia).
From randomization to hospital discharge, up to 30 days.
Nursing oxygen flow adjustments
Tidsramme: From randomization to hospital discharge, up to 30 days.

Number of oxygen flow changes and oxygen interface changes made by nursing staff per shift (morning, afternoon, night).
From randomization to hospital discharge, up to 30 days.
Number of nursing vital sign measurements per shift
Tidsramme: From randomization to hospital discharge, up to 30 days.

Total number of individual vital sign measurements taken by nursing staff per 8-hour shift, where each recording of SpO2, temperature, blood pressure, heart rate or respiratory rate counts as one measurement. For each participant, the counts are averaged across all shifts of the stay and reported as the mean number of measurements per shift.
From randomization to hospital discharge, up to 30 days.
Calls to the physician
Tidsramme: From randomization to hospital discharge, up to 30 days.

Number of calls to the physician related to desaturation, oxygen flow changes or abnormal vital signs.
From randomization to hospital discharge, up to 30 days.
Total oxygen delivered
Tidsramme: From randomization to hospital discharge, up to 30 days.

Total oxygen delivered (litres) during the hospital stay.
From randomization to hospital discharge, up to 30 days.
Mean oxygen flow
Tidsramme: From randomization to hospital discharge, up to 30 days.

Mean oxygen flow (litres per minute) delivered during the hospital stay.
From randomization to hospital discharge, up to 30 days.
Length of hospital stay
Tidsramme: From randomization to hospital discharge, up to 30 days.

Days from randomization to hospital discharge.
From randomization to hospital discharge, up to 30 days.
Escalation to a higher level of respiratory support
Tidsramme: From randomization to hospital discharge, up to 30 days.

Proportion of participants requiring high-flow nasal cannula, non-invasive ventilation, or transfer to the Respiratory Intermediate Care Unit or ICU due to respiratory or hemodynamic deterioration.
From randomization to hospital discharge, up to 30 days.
Device alerts
Tidsramme: From randomization to hospital discharge, up to 30 days.

Number of alerts generated by EMILY.AI related to oxygenation or vital signs per participant during the hospital stay.
From randomization to hospital discharge, up to 30 days.
Percentage of device alerts corresponding to a true clinical change
Tidsramme: From randomization to hospital discharge, up to 30 days.

Percentage of EMILY.AI alerts confirmed by the clinical team as corresponding to a true clinical change.
From randomization to hospital discharge, up to 30 days.
Change in arterial partial pressure of oxygen (PaO2)
Tidsramme: At randomization and at hospital discharge (up to 30 days).

Change in PaO2 (mmHg) measured by arterial blood gas analysis between randomization and hospital discharge.
At randomization and at hospital discharge (up to 30 days).
Change in arterial partial pressure of carbon dioxide (PaCO2)
Tidsramme: At randomization and at hospital discharge (up to 30 days).

Change in PaCO2 (mmHg) measured by arterial blood gas analysis between randomization and hospital discharge.
At randomization and at hospital discharge (up to 30 days).
Change in arterial pH
Tidsramme: At randomization and at hospital discharge (up to 30 days).

Change in arterial pH (pH units) measured by arterial blood gas analysis between randomization and hospital discharge.
At randomization and at hospital discharge (up to 30 days).
Change in dyspnoea measured with the modified Borg Dyspnoea Scale
Tidsramme: At randomization and at hospital discharge (up to 30 days).

Change between randomization and hospital discharge in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome.
At randomization and at hospital discharge (up to 30 days).
Satisfaction with oxygen therapy measured with a 5-point Likert scale
Tidsramme: At hospital discharge (up to 30 days).

Participant-reported satisfaction with oxygen therapy at hospital discharge, measured with a single-item 5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores mean a better outcome.
At hospital discharge (up to 30 days).

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Intercurrent events
Tidsramme: From randomization to hospital discharge, up to 30 days.

Number of participants with falls with clinical consequences, non-respiratory nosocomial infection, acute cardiovascular events, major bleeding, decompensation of non-respiratory comorbidity, social problems prolonging stay, or unplanned procedures.
From randomization to hospital discharge, up to 30 days.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Aether Tech S.L.

Samarbejdspartnere

Hospital Universitario Fundación Jiménez Díaz

Efterforskere

  • Ledende efterforsker: Sarah Beatrice Heili Frades, MD, PhD, MD, PhD, Hospital Universitario Fundación Jiménez Díaz

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. februar 2027

Primær færdiggørelse (Anslået)

1. december 2027

Studieafslutning (Anslået)

1. december 2027

Datoer for studieregistrering

Først indsendt

28. oktober 2026

Først indsendt, der opfyldte QC-kriterier

9. november 2026

Først opslået (Faktiske)

12. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • FJD-EMILY-23-02-WARD
  • FJD-EMILY-23-02 (Anden identifikator: Aether Tech S.L.)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner